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Abstract First-generation, reversible epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs),
erlotinib and gefitinib, represented an important addition to
the treatment armamentarium for non-small-cell lung
cancer (NSCLC) patients with activating EGFR mutations.
However, all patients inevitably develop acquired resis-
tance to these agents, primarily due to secondary EGFR
mutations, molecular aberrations affecting other signaling
pathways, or transformation to small-cell histology. It was
hypothesized that development of second-generation TKIs
with broader inhibitory profiles could confer longer-lasting
clinical activity and overcome acquired resistance to first-
generation inhibitors. Here, we review the development of
afatinib, an irreversible ErbB family blocker that potently
inhibits signaling of all homodimers and heterodimers
formed by the EGFR, human epidermal growth factor
receptor (HER)-2, HER3, and HER4 receptors. In two
phase III trials in patients with EGFR mutation-positive
NSCLC, first-line afatinib significantly improved progres-
sion-free survival (PFS) and health-related quality of life
versus standard-of-care chemotherapy. Moreover, in pre-
planned sub-analyses, afatinib significantly improved
overall survival in patients harboring EGFR Del19 muta-
tions. Afatinib has also demonstrated clinical activity in
NSCLC patients who had progressed on erlotinib/gefitinib,
particularly when combined with cetuximab, and offers
‘treatment beyond progression’ benefit when combined
with paclitaxel versus chemotherapy alone. Furthermore, a
recent phase III study demonstrated that PFS was signifi-
cantly improved with afatinib versus erlotinib for the sec-
ond-line treatment of patients with squamous cell
carcinoma of the lung. The activity of afatinib in both first-
line and relapsed/refractory settings may reflect its ability
to irreversibly inhibit all ErbB family members. Afatinib
has a well-defined safety profile with characteristic gas-
trointestinal (diarrhea, stomatitis) and cutaneous (rash/
acne) adverse events.
Key Points
Afatinib is an irreversible ErbB family blocker that
potently inhibits signaling from all ErbB family
receptor homodimers and heterodimers.
In two large phase III trials, first-line afatinib
significantly improved overall survival versus
chemotherapy in non-small-cell lung cancer
(NSCLC) patients specifically harboring epidermal
growth factor receptor (EGFR) Del19 mutations, as
well as progression-free survival and patient-
reported outcomes in patients with EGFR mutation-
positive disease regardless of mutation type.
Afatinib has demonstrated improved overall survival
and progression-free survival versus erlotinib in
patients with squamous cell carcinoma of the lung. It
has also demonstrated promising activity in NSCLC
patients with brain metastases, in patients who have
failed prior chemotherapy and/or first-generation
reversible EGFR tyrosine kinase inhibitors, and
when continued in combination with paclitaxel
beyond disease progression after monotherapy.
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Over the last few decades, many advances have been made
in the treatment of non-small-cell lung cancer (NSCLC),
including improvements in cytotoxic chemotherapy regi-
mens and the discovery of new targeted therapies [1].
Despite these advances, NSCLC is still difficult to treat.
Patients with NSCLC typically present with advanced
disease, where localized therapy is not a viable option
[2]. Platinum-based chemotherapy, the standard first-line
therapy for many patients, can prolong survival by
8–12 months in some cases and improve disease-related
symptoms and quality of life (QoL) [3]; however, out-
comes are generally poor and tolerability is often a concern
[3]. For patients with refractory/relapsed disease, approved
second-line treatments include docetaxel, pemetrexed, or
erlotinib [3], although survival benefits with these agents
are modest [4–6]. The US FDA withdrew approval for
gefitinib in this setting following the phase III ISEL
(IRESSA Survival Evaluation in Lung Cancer) study that
failed to demonstrate a significant overall survival (OS)
benefit over placebo [7]; however, subsequent studies have
shown second-line gefitinib to be non-inferior to docetaxel,
with improved tolerability [8]. In part, the difficulty of
treating NSCLC arises from the strikingly heterogeneous
nature of the disease. In recent years, numerous oncogenic
driver mutations have been identified in NSCLC, which has
led to development of some molecularly targeted anti-
cancer agents [9]. To date, the following have been iden-
tified as druggable targets: rearrangements in the anaplastic
lymphoma kinase (ALK) gene (3–5 % of patients) and
mutations in the epidermal growth factor receptor (EGFR)
[2, 9–11].
EGFR is a member of a family of four structurally
related receptor tyrosine kinases, the ErbB family kinases
[12, 13]. In humans, this includes human epidermal growth
factor 1 (HER1; EGFR, ErbB1), HER2 (Neu, ErbB2),
HER3 (ErbB3), and HER4 (ErbB4). ErbB family proteins
form homodimers, heterodimers, and possibly higher-order
oligomers [12, 13]. The normal physiological role of the
ErbB family is regulation of cellular proliferation [12].
Dysregulated signaling through ErbB proteins has been
associated with the development of a variety of cancers,
including NSCLC [12, 13]. Many patients with NSCLC
have somatic mutations of EGFR that lead to aberrant
constitutive signaling via EGFR and its downstream net-
works; these abnormalities have been reported in about
50 % of Asian patients and 10–15 % of Caucasian patients
with lung adenocarcinoma [14]. Of the known EGFR
mutations, the most common are exon 19 deletions (Del19)
and an L858R point mutation (L858R) [15]. Tumors
with EGFR-activating mutations can become completely
dependent on EGFR activity to stimulate downstream cell
signaling networks (‘oncogene addiction’). In this instance,
blockade of EGFR with oral tyrosine kinase inhibitors
(TKIs) blocks proliferation and initiates apoptosis [16].
The first-generation reversible EGFR-TKIs, erlotinib
and gefitinib, are approved first-line therapies for patients
with NSCLC harboring activating EGFR mutations. In
randomized phase III trials, both agents demonstrated
improved progression-free survival (PFS) and response
rates versus standard platinum-based chemotherapy in this
setting (Table 1) [17–23]. Unfortunately, however, virtu-
ally all patients who respond inevitably develop acquired
resistance to these agents, and tumors rapidly regrow [24].
Moreover, neither erlotinib nor gefitinib have demonstrated
an OS benefit over chemotherapy [17, 25–30]. Conse-
quently, there has been intensive research into (1) mecha-
nisms of resistance to first-generation inhibitors; (2)
development of newer, more potent ErbB receptor family
inhibitors that may offer (a) prolonged response in a first-
line setting or (b) viable treatment options following the
failure of first-generation inhibitors. In this review, we
discuss the rationale for, and development of, second-
generation TKIs with a focus on afatinib an irreversible,
ErbB family blocker.
2 First-Generation Epidermal Growth Factor
Receptor (EGFR) Tyrosine Kinase Inhibitors
(TKIs) in the Treatment of Non-Small-Cell Lung
Cancer (NSCLC)
First-generation EGFR-TKIs bind reversibly to the kinase
domain of the enzyme, inhibiting both mutated and, to a
lesser extent, wild-type EGFR [31]. They interrupt EGFR
signaling through blockade of autophosphorylation, fol-
lowing competitive binding versus adenosine triphosphate
(ATP) at the receptor intracellular catalytic domain [32,
33]. Initial phase III clinical trials of gefitinib versus
chemotherapy (IPASS [Iressa Pan-Asia study] and First-
SIGNAL [First-line Single-agent Iressa versus Gemc-
itabine and cisplatin trial in Never-smokers with Adeno-
carcinoma of the Lung]; Table 1) [17, 20] were undertaken
in patients who were not preselected based on EGFR
mutation status; however, subgroup analyses and subse-
quent independent studies demonstrated that activating
EGFR mutations were strongly predictive of improved
outcomes with EGFR-TKIs [17, 20, 34, 35]. Consequently,
additional phase III studies of gefitinib and erlotinib were
conducted in preselected patients with activating EGFR
mutations [18, 19, 21, 23], leading to regulatory approval
of both agents (Table 1).
In addition to the IPASS and First-SIGNAL trials con-
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improvements in PFS with first-line gefitinib compared
with platinum-doublet chemotherapy were reported in two
phase III studies (NEJ002, WJTOG3405) in Japanese
patients with EGFR mutation-positive NSCLC (Table 1)
[18, 19]. Currently, gefitinib is approved in Europe for the
treatment of locally advanced or metastatic NSCLC with
sensitizing EGFR mutations [36]. In the USA, gefitinib is
restricted to patients who, in the opinion of the treating
physician, are currently benefitting from, or have previ-
ously benefitted from, treatment with this agent [37].
In a phase III European trial (EURTAC [European tar-
ceva versus chemotherapy]) comparing erlotinib with
platinum-doublet chemotherapy in patients with advanced
NSCLC and activating EGFR mutations, a significant
improvement in median PFS (Table 1) and better tolera-
bility was observed with erlotinib versus chemotherapy
[21]. Similar findings for erlotinib were observed in a
clinical trial (OPTIMAL) in Chinese patients [23], and
National Comprehensive Cancer Network (NCCN) guide-
lines were amended in 2011 on the strength of these data.
In May 2013, erlotinib was approved by the US FDA for
first-line treatment of patients whose tumors have common
activating EGFR mutations [38].
Erlotinib and gefitinib are also sometimes recommended
as second- or third-line therapy in patients with NSCLC [2].
In the case of erlotinib, this recommendation is independent
of mutation status, based on a placebo-controlled, phase III
trial in unselected relapsed/refractory NSCLC patients
(BR21) [6]. However, subsequent studies have indicated that
the activity of erlotinib in second-/third-line settings is lar-
gely restricted to patients with activating EGFRmutations. In
a phase III trial (TAILOR [Tarceva Italian Lung Optimiza-
tion tRial]), erlotinib was compared with docetaxel as sec-
ond-line therapy in patients with NSCLC and wild-type
EGFR. In this study, PFS was significantly longer with
docetaxel than with erlotinib in the overall study population
and the subgroup of patients with adenocarcinoma histology;
PFS was similar between treatment groups in the subgroup of
patients with squamous histology [39]. In another phase III
trial (DELTA [Docetaxel and Erlotinib Lung Cancer Trial]),
in an EGFR-unselected patient population, erlotinib failed to
show an improvement in PFS or OS versus docetaxel in a
second-/third-line setting [40]. Taken together, these findings
suggest that chemotherapy remains the most effective treat-
ment option (albeit with modest activity) in the majority of
EGFR-wild-type patients with relapsed/refractory NSCLC,
although further studies with EGFR-TKIs in patients with
squamous cell histology independent of EGFR mutation
status are ongoing. However, despite the activity observed in
the relapsed/refractory setting, chemotherapy, particularly
docetaxel, is associated with poor tolerability [39]. There-
fore, there remains an unmet medical need for more effective
and/or better tolerated second-line treatment options.
3 Resistance to First-Generation EGFR-TKIs
Patients with NSCLC tumors harboring EGFR mutations
inevitably develop resistance to first-generation EGFR-
TKIs [24]. The most common resistance mechanism
defined to date (50–60 % of patients) is the accrual of a
T790M missense mutation in exon 20 (T790M) [41–43].
This abnormality interferes with the binding of inhibitors
of EGFR through steric hindrance [44]. Other acquired
resistance mechanisms are currently less well understood,
although there is evidence that activation of other tyrosine
kinase receptors, either due to overexpression or mutations,
leads to compensatory signaling via proliferative pathways
including the phosphoinositide 3-kinase/protein kinase
B/mammalian target of rapamycin (PI3K/AKT/mTOR) and
Janus kinase 2/signal transducer and activator of tran-
scription 3 (JAK2/STAT3) cascades [45]. Receptors
implicated in resistance to EGFR-TKIs include the MET
receptor, a trans-membrane tyrosine kinase encoded by the
proto-oncogene, MET and the insulin-like growth factor
(IGF)-1 receptor [46–48]. Notably, other members of the
ErbB family of receptors have also been implicated. Gene
amplification or protein overexpression of HER2 can
induce resistance to EGFR-TKIs [49]. Furthermore, con-
tinuous exposure to first-generation inhibitors can confer
overexpression of HER3 as a result of loss of AKT-medi-
ated negative feedback signaling [50]. Efforts to overcome
these resistance mechanisms in NSCLC patients have
included the development of irreversible ErbB family
inhibitors that may provide more durable and prolonged
responses in the first-line setting, as well as offering a
potential treatment option in patients with acquired resis-
tance to erlotinib/gefitinib. Other proposed, yet poorly
understood, mechanisms of resistance include transforma-
tion to small-cell histology [43] and epithelial to mes-
enchymal transition [51].
4 Second-Generation TKIs: An Overview
Based on the rationale above, several second-generation
TKIs have been assessed in preclinical studies as well as in
the clinic in patients with NSCLC. In brief, these include
the following.
4.1 Dacomitinib
Dacomitinib irreversibly inhibits EGFR, HER2, and HER4
and blocks signaling through all ErbB homodimers and
heterodimers [52, 53]. In preclinical studies, dacomitinib
was reported to inhibit EGFR signaling in tumors/cells
harboring several different EGFR mutations, including
T790M [52]. Dacomitinib has been assessed in both first-
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line and relapsed/refractory settings in patients with
NSCLC. In a recent phase II study, dacomitinib was
reported to deliver a median PFS of 18.2 months in patients
who had treatment-naı¨ve NSCLC with activating EGFR
mutations [54]. A randomized phase III trial comparing
dacomitinib and gefitinib in this setting is ongoing
(ARCHER [Advanced research for cancer targeted pan-
HER therapy] 1050). However, recent studies with
dacomitinib in the relapsed/refractory setting have failed to
achieve their primary objectives. In the phase III ARCHER
1009 study, which compared dacomitinib with erlotinib in
patients with NSCLC who had previously received up to
two chemotherapy regimens, median PFS was 2.6 months
in both groups [55]. In the phase III BR.26 trial, which
assessed dacomitinib versus placebo in patients who had
previously received chemotherapy and a first-generation
reversible EGFR-TKI, there was no significant difference
in OS between the two treatment arms, albeit PFS was
significantly longer in patients who received dacomitinib
(median 2.7 vs. 1.4 months; p\ 0.0001).
4.2 Neratinib
Neratinib is an irreversible inhibitor of EGFR and HER2.
In preclinical studies, it was more effective than gefitinib at
suppressing cell proliferation in lung cancer cell lines,
including cells harboring the T790M mutation [56]. Nera-
tinib was assessed in a phase II study of patients with
advanced NSCLC who had previously received at least
12 weeks of therapy with gefitinib or erlotinib. Response
rates in this trial were very low; 3 % of patients with
activating EGFR mutations and no patients with T790M
achieved an objective response (OR) [57]. A total of 50 %
of patients developed grade 3 diarrhea at the previously
determined maximum tolerated dose (MTD) of
320 mg/day [58], and the phase II trial dose was subse-
quently reduced to 240 mg/day.
4.3 Afatinib
Afatinib covalently binds to EGFR, HER2, and ErbB4
[59]. Such covalent binding irreversibly inhibits the tyr-
osine kinase activity of these receptors, resulting in reduced
auto- and trans-phosphorylation within the ErbB dimers
and inhibition of important steps in the signal transduction
of all ErbB receptor family members (Fig. 1). The other
ErbB family member, ErbB3, lacks intrinsic kinase activity
but forms active heterodimers with other family members,
particularly HER2 [60]. Afatinib effectively silences sig-
naling of all ErbB family heterodimers, including HER2/
ErbB3 (Fig. 1) [59]. The irreversible inhibition of multiple
ErbB family receptors by afatinib results in more potent
and prolonged suppression of receptor kinase activity
compared with reversible first-generation EGFR-TKIs [31,
59, 61]. Afatinib is currently approved in the USA for the
first-line treatment of patients with metastatic NSCLC
whose tumors have EGFR exon 19 deletions or exon 21
substitution mutations as detected by an FDA-approved test
[62]. Afatinib is also approved for patients with NSCLC in
over 40 countries worldwide, including the EU, Japan,
Taiwan, and Canada. In the EU, it is indicated for patients
with TKI-naı¨ve NSCLC harboring activating EGFR
mutations [63]. The remainder of this review focuses on the
preclinical and clinical development of afatinib in patients
with NSCLC.
5 Preclinical Development of Afatinib
In cell-free in vitro kinase assays, afatinib demonstrated
potent inhibition of wild-type EGFR, HER2, and ErbB4 at
low nanomolar concentrations, whereas reversible TKIs
erlotinib and gefitinib only inhibited EGFR (Table 2) [59].
Moreover, both cell-free assays and cell-based proliferation
Fig. 1 Irreversible inhibition of ErbB receptor family signaling by
afatinib. Covalent binding of afatinib to the ErbB family of receptors
inhibits downstream signaling of all homodimers and heterodimers
formed by these receptors [59, 61]. AKT protein kinase B, EGFR
epidermal growth factor receptor, ERK extracellular signal-regulated
kinase, HER2 human epidermal growth factor receptor 2 (ErbB2),
MEK mitogen-activated protein kinase kinase, mTOR mammalian
target of rapamycin, P13K phosphoinositide 3-kinase, RAF rapidly
accelerated fibrosarcoma, RAS rat sarcoma
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assays have shown that afatinib has potent inhibitory
activity in the presence of the common EGFR-activating
mutations, L858R and Del19 [59, 61]. In contrast with
erlotinib and gefitinib, afatinib was also active against
NSCLC cells that overexpress HER2 (Table 2).
Afatinib inhibited cellular growth and induced apoptosis
in several tumor cell lines, and resulted in tumor shrinkage
in xenograft models of various cancer types, including
NSCLC, pancreatic cancer, colorectal cancer, and head and
neck squamous cell cancer [64]. Afatinib also demonstrated
activity in preclinical models of tumor cells resistant to
reversible EGFR inhibitors, suggesting that irreversible
ErbB family blockade could be effective in patients with
reversible EGFR-TKI-resistant disease [64, 65]. Indeed, in
cell-free kinase assays, afatinib inhibited EGFR harboring
L858R/T790M at low nanomolar concentrations (half
maximal effective concentration [EC50], 9–10 nM;
Table 2). Furthermore, afatinib inhibited cell growth in
cultured lung cancer cells (EC50, 99 nM) and a lung cancer
xenograft model harboring L858R/T790M [61, 64]. In
comparison, EC50 values for erlotinib and gefitinib against
L858R/T790M were [500 nM in cell-free kinase assays
(Table 2) and[4000 nM in cultured lung cancer cells [61].
Taken together, the potent irreversible inhibition of
signaling from all ErbB family receptor dimers formed by
EGFR, HER2, and ErbB4, and preclinical antitumor
activity observed in both EGFR-TKI-naı¨ve and resistant
cultured cells and xenograft models, provided biological
rationale for the evaluation of afatinib in clinical trials.
6 Clinical Trials of First-Line Afatinib in Patients
with NSCLC and Activating EGFR Mutations:
LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
6.1 Trial Design
The LL3 (LUX-Lung 3; 345 patients recruited globally)
and LL6 (364 patients recruited in China, South Korea, and
Thailand) trials are the largest randomized, phase III trials
ever to be undertaken in treatment-naı¨ve patients with
EGFR mutation-positive advanced NSCLC [66–68]. In
contrast to the gefitinib and erlotinib registration studies,
recruitment was not restricted to patients with tumors
harboring Del19 and/or L858R; the trial designs of LL3 and
LL6 also incorporated patients with uncommon EGFR
mutations (including T790M, exon 20 insertions, G719X,
S768I, and L861Q, alone or as complex mutations in two or
more exons). Patients were randomized (2:1) to afatinib
(40 mg/day) or up to six cycles of standard-of-care plat-
inum-based chemotherapy (cisplatin ? pemetrexed [LL3]
or cisplatin ? gemcitabine [LL6]; selection based on the
regulatory requirements of the different regions). It should
be noted that cisplatin ? pemetrexed was considered a
state-of-the-art chemotherapy regimen when LL3 was
designed and represented a more challenging comparator
than used in other trials of EGFR-TKIs versus
chemotherapy [69].
The primary endpoint of LL3 and LL6 was PFS, by
prespecified independent central review; the key secondary
endpoint was OS. Both trials fully integrated comprehen-
sive patient-reported outcomes (PROs) related to func-
tional health status/QoL and lung cancer-related
symptoms; these were evaluated using the European
Organisation for Research and Treatment of Cancer
(EORTC) QoL Questionnaire C30 (QLQ-C30) and its lung
cancer-specific module (QLQ-LC13) (Table 3) [66, 67,
70].
6.2 Primary Endpoint: Progression-Free Survival
First-line afatinib significantly prolonged median PFS
versus chemotherapy in both LL3 (11.1 vs. 6.9 months;
hazard ratio [HR] 0.58 [95 % confidence interval (CI)
0.43–0.78; p = 0.001]) and LL6 (11.0 vs. 5.6 months; HR
0.28 [95 % CI 0.20–0.39; p = 0.0001]; Table 1; Fig. 2a/b)
[66, 67]. Furthermore, subgroup analyses showed that the
PFS benefit was apparent across most clinically relevant
subgroups (age, sex, race, Eastern Cooperative Oncology
Group [ECOG] performance status). When the analysis
Table 2 Inhibitory potency of
afatinib, erlotinib, and gefitinib
against ErbB family members in
cell-free kinase assays and cell
proliferation assays of various
human lung cancer cell lines
(nanomolar concentration
causing 50 % inhibition
(adapted from Solca et al. and
Li et al. [59, 61])
EGFRWT EGFRL858R EGFRL858R/T790M HER2 HER4
Cell-free kinase assays
Afatinib 0.2–0.7 0.2–0.4 9–10 7–25 0.7–1.7
Erlotinib 0.9–1.7 1.1–2.7 1520–3562 238–698 579–756
Gefitinib 0.4–4.7 0.8–1.4 534–1267 416–1830 293–323
Cell proliferation assays
Afatinib 60 0.7 92–225 12–56 NA
Erlotinib 110 40 [4000 [4000 NA
Gefitinib 157 5 [4000 [4000 NA
EGFR epidermal growth factor receptor, HER2 human epidermal growth factor receptor 2 (ErbB2), WT
wild-type, NA not available
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was restricted to patients with common EGFR mutations
only, the PFS advantage over chemotherapy was more
pronounced. The PFS benefit versus chemotherapy con-
ferred by afatinib, gefitinib, and erlotinib in phase III trials
is summarized in Table 1. In the context of previous
studies with erlotinib and gefitinib, the median PFS values
of 13.6 and 11.0 months achieved with afatinib appear
favorable. However, a number of recent meta-analyses
have failed to detect any significant differences in efficacy
between afatinib and first-generation TKIs [71–73],
emphasizing the need for head-to-head data. Nevertheless,
a recently published network meta-analysis showed an
estimated probability of being best for afatinib over all
other treatments for PFS of 70 versus 27 % for erlotinib
and 3 % for gefitinib [74].
Interestingly, afatinib also appears to be active in a
subset of patients with certain uncommon EGFR muta-
tions. In a pooled analysis of LL3, LL6, and the phase II
LL2 study [75], patients with rare mutations/duplications in
exons 18–21 (n = 38) who received afatinib had a median
PFS of 10.7 months [76]. However, for 14 patients with de
novo T790M mutations, outcomes were variable but gen-
erally poor. In these patients, the response rate was 14.3 %,
median PFS was 2.9 months, and OS was 14.9 months
[76]. Given the small sample size, these data should be
interpreted with caution. However, it may be that
chemotherapy may be the most appropriate treatment
option in patients with de novo T790M mutations.
Nevertheless, given that afatinib shows preclinical activity
against T790M in vitro and in vivo, further studies are
warranted in patients with T790M-positive tumors. One
ongoing study, for example, is examining the feasibility of
intermittent high-dose afatinib in such patients
(NCT01647711). In LL3, LL6, and LL2, outcomes were
also poor against tumors harboring exon 20 insertions
(median PFS 2.7 months, n = 23).
Another sub-analysis (of the LL3 study) indicated that
afatinib is also beneficial in patients with brain metastases
[77]. In this subgroup (n = 35), median PFS with afatinib
versus chemotherapy was 11.1 vs. 5.4 months (HR 0.52
[95 % CI 0.22–1.23; p = 0.13]). Among patients with
intracranial progression (n = 10), median time to pro-
gression was 11.6 months with afatinib versus 5.5 months
with chemotherapy [77]. Furthermore, a compassionate use
program indicated that afatinib had clinical activity in
NSCLC patients with central nervous system metastases
who had progressed on chemotherapy and an EGFR-TKI
[78]. Further analyses of afatinib in NSCLC patients har-
boring uncommon EGFR mutations or with brain metas-
tases are ongoing.
6.3 Key Secondary Endpoint: Overall Survival
Median follow-up for OS was 41 and 33 months in LL3
and LL6, respectively [68]. In the overall dataset (all EGFR
mutations), no significant difference in median OS was
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observed between the afatinib and chemotherapy arms
(LL3 28.2 vs. 28.2 months; HR 0.88 [95 % CI 0.66–1.17;
p = 0.39]; LL6 23.1 vs. 23.5 months; HR 0.93 [95 % CI
0.72–1.22; p = 0.61]). Interestingly, in a prespecified
analysis, median OS was significantly improved with afa-
tinib compared with chemotherapy in patients harboring
Del19 mutations in both LL3 (33.3 vs. 21.1 months; HR
0.54 [95 % CI 0.36–0.79; p = 0.0015]) and LL6 (31.4 vs.
18.4 months; HR 0.64 [95 % CI 0.44–0.94; p = 0.0229];
Table 1; Fig. 3a/b); no OS difference was observed in the
L858R mutation-positive subgroup. However, in a pre-
specified analysis of median OS in patients with common
mutations (Del19/L858R), a trend towards OS benefit was
observed (LL3 31.6 vs. 28.2 months; HR 0.78 [95 % CI
0.58–1.06; p = 0.11]; LL6 23.6 vs. 23.5 months; HR 0.83
[95 % CI 0.62–1.09; p = 0.18]; Table 1). Afatinib is the
first agent to demonstrate improved OS versus standard-of-
care platinum-doublet chemotherapy in a molecularly-de-
fined population of patients with NSCLC. No head-to-head
studies are currently available to allow direct comparison
of OS achieved with afatinib versus first-generation EGFR-
TKIs. However, a phase IIb trial comparing first-line afa-
tinib versus gefitinib with EGFR mutation-positive lung
adenocarcinoma is ongoing (NCT01466660).
While the majority of patients in LL3, and all patients in
LL6, were Asian, the OS benefit with afatinib over
chemotherapy in patients harboring the EGFR Del19
mutation was independent of ethnicity; OS in non-Asian
patients (n = 46) was 33.6 vs. 20.0 months (HR 0.45
[95 % CI 0.21–0.95; p = 0.03]) [68]; OS in Asian patients
(LL3 and LL6 combined; n = 309) was 31.7 vs.
21.1 months (HR 0.61 [95 % CI 0.46–0.82; p\ 0.01])
[79]. Furthermore, a significant OS improvement with
afatinib versus chemotherapy in patients harboring the
Del19 mutation was observed in the Chinese subgroup of
LL6 (n = 166; 31.6 vs. 16.3 months; HR 0.61 [95 % CI
0.41–0.91; p = 0.015]) and in the Japanese subgroup of
LL3 (n = 39; 46.9 vs. 31.5 months; HR 0.34 [95 % CI
0.13–0.87; p = 0.018]) [80, 81]. The more pronounced OS
benefit observed with afatinib in Japanese patients may
reflect greater access to subsequent therapies following
disease progression [68]. These subgroup data support the
applicability of the OS findings in LL3 and LL6 to all
patients with EGFR mutation-positive disease, regardless
of race/ethnicity.
In contrast to afatinib, neither erlotinib nor gefitinib
demonstrated an OS benefit versus chemotherapy in
patients harboring Del19 or, indeed, L858R mutation-pos-
itive disease [21, 26, 28]. The lack of OS benefit with
gefitinib or erlotinib versus chemotherapy, either in total
datasets or in patients with the EGFR Del19 mutation
(Table 1) [17, 25–30], has been attributed, at least partially,
to post-progression therapy with EGFR-TKIs in patients
initially randomized to chemotherapy [17, 25–27, 29, 30].
In this context, it is interesting to note that crossover rates
in LL3 and LL6 were similar to those in phase III trials
Fig. 2 Progression-free survival for afatinib versus chemotherapy in
a Lux-Lung 3 [66] and b Lux-Lung 6 [67]. a Sequist, LV et al: J Clin
Oncol 31 (27), 2013: 3327–34. Reprinted with permission.  (2013)
American Society of Clinical Oncology. All rights reserved.
b Reprinted from The Lancet Oncology, Vol. 15, Wu YL et al,
Afatinib versus cisplatin plus gemcitabine for first-line treatment of
Asian patients with advanced non-small-cell lung cancer harbouring
EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3
trial, pp. 213–22, 2014, with permission from Elsevier. CI confidence
interval, Cis/Gem cisplatin/gemcitabine, Cis/Pem cisplatin/peme-
trexed, PFS progression-free survival
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with gefitinib or erlotinib in this setting [21, 23, 25–27].
Furthermore, in LL3, a significant OS benefit with afatinib
versus chemotherapy was observed in Japanese patients
despite the fact that nearly all chemotherapy-treated
patients in this sub-analysis received an EGFR-TKI fol-
lowing disease progression [80].
Taken together, OS analyses in LL3 and LL6 indicate
that afatinib should be considered as a first-line therapy
for patients with EGFR Del19 mutation-positive lung
adenocarcinoma [82], and is also a valuable option for
patients with EGFR mutation-positive NSCLC harboring
other common mutations (L858R) as well as a subset of
patients with certain uncommon mutations. The signifi-
cantly and substantially longer OS achieved by afatinib in
Del19 patients further suggests that patients with EGFR
Del19 and L858R mutation-positive disease should be
studied separately in future trials evaluating TKIs in
patients with EGFR mutation-positive NSCLC.
6.4 Patient-Reported Outcomes
Disease-related symptoms, treatment-related adverse
events (AEs), and treatment efficacy all substantially
influence patients’ QoL [83]. In order to assess the effect of
afatinib on QoL, both LL3 and LL6 fully integrated com-
prehensive PRO evaluation into outcome analyses
(Table 3). In contrast with IPASS (which utilized Func-
tional Assessment of Cancer Therapy indices) and EUR-
TAC (where insufficient PRO data were collected for
analysis), the afatinib trials assessed both EORTC QLQ-
LC13 and QLQ-C30. This provided a complete picture of
both lung cancer-related symptoms and symptoms related
to treatment. These analyses demonstrated that afatinib
improved prespecified lung cancer-related symptoms
(cough, dyspnea, and pain) and delayed their deterioration
versus chemotherapy. In LL3, afatinib significantly
delayed time to deterioration for cough (p = 0.007) and
dyspnea (p = 0.015), but not pain (p = 0.19), and was
associated with improved mean scores over time for cough
and dyspnea (both p\ 0.001). Improvements in mean
scores over time were also observed with afatinib versus
chemotherapy for functional health status/QoL (p = 0.015)
and physical (p\ 0.001), role (p = 0.004), and cognitive
(p = 0.007) functioning [66, 70]. In LL6, afatinib signifi-
cantly delayed time to deterioration for cough
(p\ 0.0001), dyspnea (p\ 0.0001), and pain (p = 0.027)
versus chemotherapy, and was associated with improve-
ments in mean scores over time for each symptom (all
p\ 0.0001). Furthermore, more patients treated with afa-
tinib versus chemotherapy showed longer time to deterio-
ration (p = 0.0002), better mean scores over time
(p\ 0.0001), and improvements from baseline in global
health status/QoL (p\ 0.0001) [67].
6.5 Safety/Tolerability
In both LL3 and LL6, afatinib was associated with pre-
dictable and manageable AE profiles, and low discontinu-
ation rates due to treatment-related AEs. In LL3, grade 3 or
higher treatment-related AEs occurred in 112 (49 %)
patients receiving afatinib and 53 (48 %) patients receiving
chemotherapy [66]. The most common treatment-related
AEs (all grades/grade 3 or higher) were diarrhea (95/14 %)
Fig. 3 Overall survival in patients with exon 19 deletions in LUX-
Lung 3 and LUX-Lung 6 [68]. Reprinted from The Lancet Oncology,
Vol. 16, Yang JC et al, Afatinib versus cisplatin-based chemotherapy
for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and
LUX-Lung 6): analysis of overall survival data from two randomised,
phase 3 trials, pp. 141–51, 2015, with permission from Elsevier. CI
confidence interval, Cis/Gem cisplatin/gemcitabine, Cis/Pem cis-
platin/pemetrexed, OS overall survival
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rash/acne (89/16 %), stomatitis/mucositis (72/9 %), and
paronychia (57/11 %) in the afatinib arm and nausea (66/
4 %), decreased appetite (53/3 %), fatigue (47/13 %), and
vomiting (42/3 %) in the chemotherapy arm. Therapy was
discontinued because of treatment-related AEs in 8 % of
those receiving afatinib and 12 % of those receiving
chemotherapy. Of the most common AEs associated with
afatinib, only diarrhea (1.3 %) and paronychia (0.9 %)
resulted in treatment discontinuation. In LL6, treatment-
related AEs grade 3 or higher occurred in 86 (36 %)
patients receiving afatinib and 68 (60 %) patients receiving
chemotherapy [67]. As with LL3, the most common
treatment-related AEs (all grades/grade 3 or higher) were
diarrhea (88/5 %), rash/acne (81/15 %), stomatitis/mu-
cositis (52/5 %), and paronychia (33/0 %) in the afatinib
arm and vomiting (81/19 %), nausea (75/8 %), decreased
appetite (41/2 %), and fatigue (36/1 %) in the chemother-
apy arm. Therapy was discontinued because of treatment-
related AEs in 6 % of patients receiving afatinib and 40 %
of patients receiving chemotherapy. The most common
cause of discontinuation in the afatinib arm was rash/acne
(2 %). No patients discontinued due to diarrhea only.
6.6 Adverse Event Management
In general, drug-related AEs were effectively managed
with supportive care and/or protocol-defined dose reduc-
tions and led to few treatment-related discontinuations [66,
67]. Of note, afatinib-treated patients were permitted to
dose-escalate from the initial 40 mg dose to 50 mg/day
after the first 21-day treatment cycle if no drug-related AEs
higher than grade 1 were experienced, while dose reduc-
tions in 10 mg decrements to a minimum final dose of
20 mg were recommended for patients experiencing drug-
related grade 3 or selected prolonged grade 2 AEs [66, 67].
This active management of AEs associated with afatinib
facilitates treatment compliance and improvements in
PROs, and allows patients to achieve maximum therapeutic
benefit with this agent [84, 85].
In LL3, pharmacokinetic assessments demonstrated
similar geometric mean plasma concentrations of afatinib
for all permitted dose groups (20, 30, 40, and 50 mg) after
tolerability-guided dose adjustments [66]. Importantly,
protocol-defined dose reductions based on individual
patient AEs were shown to reduce excessive plasma con-
centrations of afatinib, thereby optimizing patient exposure
to the active drug as well as managing tolerability without
compromising efficacy [66].
6.7 Summary
In two large phase III trials, afatinib demonstrated OS
benefit versus chemotherapy in patients harboring Del19
mutations, the most common EGFR aberration in patients
with NSCLC. Based on these observations, some com-
mentators have concluded that afatinib should be con-
sidered as a first-line therapy for patients with EGFR
Del19 mutation-positive lung adenocarcinoma [68, 82].
Although no significant difference in OS was observed in
patients harboring the L858R mutation, significant
improvements over chemotherapy in PFS and PROs of
disease-related symptoms and QoL, as well as a pre-
dictable and manageable safety profile in all patients with
EGFR mutation-positive NSCLC, including the L858R
mutation, suggest an important clinical benefit with afa-
tinib in patients with EGFR mutation-positive disease
[66–68].
7 Clinical Trials of Afatinib in the Relapsed/
Refractory Setting in Patients with NSCLC
7.1 LUX-Lung 1 (LL1)
In this phase IIb/III trial, afatinib monotherapy
(50 mg/day) was evaluated versus placebo in patients
(n = 585) with stage IIIb or IV lung adenocarcinoma fol-
lowing failure of up to two lines of chemotherapy and
C12 weeks of erlotinib and/or gefitinib [86, 87]. The pri-
mary endpoint was OS; secondary endpoints included PFS
and OR; health-related QoL was also assessed.
A positive test for EGFR mutation status was not
required for enrollment; however, the EGFR mutation
status of 141 patients was known, and 68 % of these
patients had activating EGFR mutations. Clinical endpoints
were assessed in a subpopulation of patients who were
clinically enriched for EGFR mutations based on Jackman
criteria [88], i.e. patients with a known EGFR-activating
mutation plus patients who had achieved an OR or durable
stable disease (SD) for[6 months, followed by systemic
disease progression of disease, on continuous gefitinib/er-
lotinib treatment.
A significant improvement in median PFS was observed
with afatinib over placebo (3.3 vs. 1.1 months; HR 0.38
[95 % CI 0.31–0.48; p\ 0.0001]) [86]. In a subgroup
analysis of patients who met Jackman criteria of acquired
resistance (n = 214), median PFS was 4.5 versus
1.0 months in the afatinib and placebo arms, respectively
(HR 0.37 [95 % CI 0.26–0.52]). The prolongation of PFS
observed with afatinib was associated with improvements
in lung cancer-related symptoms, with a significantly
higher proportion of patients having improvements in dis-
ease-related cough (p\ 0.0001), dyspnea (p = 0.006), and
pain (p\ 0.0001) [87]. Improvements in EORTC global
health status, physical functioning, and fatigue were also
observed with afatinib (all p\ 0.05).
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Median OS was not significantly different with afatinib
versus placebo (10.8 vs. 12.0 months; HR 1.08 [95 % CI
0.86–1.35; p = 0.74]). However, of note, more patients in
the placebo group (79 %) than in the afatinib group (68 %)
received subsequent anticancer therapies following dis-
continuation of study medication, including EGFR-TKIs,
which potentially confounded the OS results. No complete
responses (CRs) were noted in either arm; partial responses
(PRs) were observed in 29 (7 %) patients in the afatinib
group and one (\1 %) patient in the placebo group. Afa-
tinib was associated with a manageable safety profile.
Diarrhea (17 %) and rash/acne (14 %) were the most
common grade 3 AEs; however, these events led to few
treatment discontinuations (3.6 and 1.8 %, respectively)
[86].
Although no OS benefit was observed with afatinib over
placebo in LL1, improvements in PFS, tumor response, and
PROs of disease-related symptoms with afatinib suggested
that this agent could potentially be of benefit to patients
with advanced NSCLC who had failed previous EGFR-
TKI therapy.
7.2 LUX-Lung 5 (LL5)
The phase III LL5 trial evaluated the efficacy and safety of
continued irreversible ErbB family blockade with afatinib
combined with paclitaxel versus investigator’s choice of
chemotherapy alone in patients with NSCLC who had
acquired resistance to prior erlotinib/gefitinib and afatinib
monotherapy [89]. The study was conducted over two
stages.
In part A, patients who had failed one or more line of
chemotherapy and erlotinib/gefitinib (after C12 weeks of
treatment) were treated with afatinib monotherapy
(50 mg/day). In part B, patients achieving C12 weeks of
benefit (CR/PR/SD) with afatinib monotherapy (n = 202)
were randomized 2:1 to receive afatinib plus paclitaxel
(40 mg/day; 80 mg/m2/week) or physician’s choice of
single-agent chemotherapy. The primary endpoint was
PFS; other endpoints included objective response rate
(ORR), OS, safety, and PROs.
Significant improvements in median PFS (5.6 vs.
2.8 months; HR 0.60 [95 % CI 0.43–0.85; p = 0.003]) and
ORR (32.1 vs. 13.2 %; HR 3.41 [95 % CI 1.41–6.79;
p = 0.005]) were observed with afatinib plus paclitaxel
compared with chemotherapy alone [89]. However, there
was no significant difference in OS (12.2 vs. 12.2 months;
HR 1.00 [95 % CI 0.70–1.43; p = 0.994]); this could
reflect differences in post-progression treatment between
arms. Patients had received at least four lines of therapy at
randomization to afatinib plus paclitaxel or chemotherapy,
and approximately 60 % of patients received at least one
subsequent therapy post-progression. More patients in the
chemotherapy arm received two additional lines of therapy
than in the afatinib plus paclitaxel arm (36 vs. 15 %).
There was a trend towards delayed time to deterioration
of dyspnea (3.1 vs. 1.8 months; HR 0.78 [95 % CI
0.55–1.09; p = 0.144]) and pain (4.3 vs. 3.5 months; HR
0.80 [95 % CI 0.56–1.14; p = 0.212]) but not cough (5.7
vs. 6.5 months; HR 1.13 [95 % CI 0.79–1.62; p = 0.505])
in patients receiving paclitaxel versus chemotherapy [90].
There was also a trend towards an increased proportion of
patients with improvements in dyspnea (45 vs. 35 %;
p = 0.222) and cough (46 vs. 36 %; p = 0.225) in patients
receiving afatinib plus paclitaxel; differences in mean
scores over time also favored afatinib plus paclitaxel for
dyspnea (-2.9; p = 0.191) and cough (-3.8; p = 0.201).
Afatinib plus paclitaxel had a manageable AE profile;
treatment-related AEs were consistent with those previ-
ously reported for each agent, with (all grades) diarrhea
(53.8 vs. 6.7 %), alopecia (32.6 vs. 15.0 %), and asthenia
(27.3 vs. 28.3 %) as the most common treatment-related
AEs observed with afatinib plus paclitaxel versus
chemotherapy [89]. This manageable AE profile and QoL
maintenance was observed despite the prolonged exposure
to afatinib plus paclitaxel (median 133 days) compared
with chemotherapy (median 51 days).
In summary, LL5 is the first randomized trial to
demonstrate prospective evidence/proof of concept for
maintaining irreversible ErbB family inhibition beyond
disease progression in oncogene-addicted lung cancer.
Overall, these findings support the hypothesis that tumors
progressing on erlotinib/gefitinib and afatinib continue to
depend on ErbB family receptor signaling and can benefit
from continuous ErbB family blockade with afatinib.
Interestingly, it was recently reported that gefitinib post-
progression (combined with cisplatin ? pemetrexed) did
not confer any clinical benefit versus chemotherapy alone
in patients with confirmed activating EGFR mutations
progressing after first-line gefitinib monotherapy [91].
8 Afatinib in Combination Regimens
8.1 Rationale
The pharmacokinetic properties of afatinib are conducive
to the development of novel combination regimens with
other drugs. Afatinib is an orally bioavailable agent that
achieves peak plasma concentrations *2–5 h after dosing
[92, 93]. Due to its high solubility (pH range 1.0–7.5),
interactions with acid-reducing drugs are not expected.
Unlike the reversible EGFR-TKIs erlotinib and gefitinib,
oxidative and cytochrome P450 (CYP) enzyme-dependent
metabolism are of negligible importance for afatinib; thus,
the potential for interaction with other agents that are either
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metabolized by, or are inhibitors or inducers of, CYP-re-
lated enzymes, is low [92, 94]. This overall low probability
of drug–drug interactions makes afatinib an attractive
combination partner for chemotherapies and other targeted
therapies. In this context, a substantial number of clinical
studies aimed to identify potential combination partners
and patients who may benefit from particular combination
therapies have been undertaken or are ongoing (e.g.
NCT01999985, NCT02191891, NCT01861223) [95–103].
8.2 Dual Inhibition of EGFR with Afatinib
and Cetuximab in TKI-Resistant EGFR-Mutant
Lung Cancer with and without T790M
Mutations
In a recent phase Ib study, afatinib combined with the anti-
EGFR monoclonal antibody, cetuximab, has demonstrated
promising activity in patients who had failed on erlotinib or
gefitinib [104]. In 126 patients treated with the MTD of
afatinib plus cetuximab, the confirmed OR rate was 29 %;
interestingly, the response rate was similar in patients
harboring T790M-positive and T790M-negative tumors (32
vs. 25 %; p = 0.341). The mode of action for the observed
clinical efficacy is currently unknown. It could be related to
the fact that the tumor cells remain dependent on ErbB
signaling (due to acquired EGFR mutations, EGFR
amplification, and/or HER2 amplification); as such,
simultaneous vertical inhibition of the intracellular domain
of the ErbB receptors with afatinib and the extracellular
domain of EGFR with cetuximab might result in increased
efficacy compared with monotherapy with either agent
[104].
These preliminary data are encouraging given that no
approved treatment options are currently available for
patients with acquired resistance to first-generation inhi-
bitors. In this context, findings from phase I dose-escalation
trials of third-generation EGFR inhibitors (designed to bind
with higher affinity to EGFR harboring T790M), including
AZD-9291, CO-1686, and HM-61713, are also promising.
These studies reported [50 % response rates in patients
with EGFR T790M-positive NSCLC who had failed pre-
vious first-generation EGFR-TKI therapy [105–107].
9 Second-Line Treatment for Patients
with Squamous Cell Carcinoma of the Lung:
LUX-Lung 8 (LL8)
Squamous histology represents approximately 30 % of
NSCLC [108], and there is a major unmet need for effec-
tive treatments in patients with squamous cell carcinoma
(SCC) of the lung. Targetable oncogenic alterations are
limited and have not yet translated to a therapeutic
paradigm. Despite the fact that EGFR mutations are rare in
tumors with squamous cell histology (\5 %) [109], afa-
tinib has shown encouraging activity in such tumor types,
including a subset of patients with SCC in LL5 [110] and
SCC of the head and neck [111]. This may reflect the
observation that SCCs often overexpress EGFR [112–114].
Furthermore, other ErbB receptors or their cognate ligands
have been shown to be overexpressed, amplified, or
mutated in patients with SCC of the lung [115–117].
LL8 is the first phase III trial to prospectively compare
second-line EGFR-TKIs in patients with SCC of the lung
[118]. In this global study, patients (n = 795) with
relapsed/refractory stage IIIb/IV SCC were randomized 1:1
to receive afatinib (40 mg/day) or erlotinib (150 mg/day).
Patients recruited to this trial had progressed after four or
more cycles of platinum-based doublet chemotherapy and
had not received prior EGFR-TKI therapy. The primary
endpoint was PFS as assessed by independent radiological
review (IRR). Secondary endpoints included OS, ORR,
disease control rate (DCR), PROs, and safety. A significant
improvement in median PFS was observed with afatinib
versus erlotinib (2.6 vs. 1.9 months; HR 0.81 [95 % CI
0.69–0.96; p = 0.010]) [118]. Notably, given the paucity
of second-line treatment options in patients with SCC of
the lung, afatinib significantly improved OS versus erloti-
nib (7.9 vs. 6.8 months; HR 0.81 [95 % CI 0.69–0.95;
p = 0.008]) [118]. DCR was significantly higher with
afatinib versus erlotinib (50.5 vs. 39.5 %; p = 0.002);
ORR was 5.5 % with afatinib and 2.8 % with erlotinib
(p = 0.055).
The overall AE profile for afatinib and erlotinib was
comparable, with grade 3 or higher AEs reported in 57.1
and 57.5 % of patients, respectively. A higher incidence of
drug-related grade 3 or higher diarrhea (10.4 vs. 2.6 %) and
grade 3 stomatitis (4.1 vs. 0.0 %) was observed with afa-
tinib, and a higher incidence of grade 3 rash/acne was
observed with erlotinib (5.9 vs. 10.4 %) [118]. Further-
more, more patients in the afatinib arm reported improved
global health status/QoL (35.7 vs. 28.3 %; p = 0.041) and
cough (43.4 vs. 35.2 %; p = 0.029) versus erlotinib. Taken
together, these findings indicate that afatinib provides a
significant improvement in PFS, OS, and DCR versus
erlotinib, with a predictable and manageable AE profile,
consistent with the mechanistic profile of EGFR inhibition,
in patients with relapsed/refractory SCC.
10 Conclusions
In patients with advanced EGFR mutation-positive
NSCLC, first-line afatinib significantly improved PFS,
PROs, and QoL versus standard-of-care platinum-doublet
chemotherapy regimens in two large phase III studies. In
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addition, afatinib demonstrated a significant OS advan-
tage versus chemotherapy in patients with NSCLC har-
boring EGFR Del19 mutations. These findings suggest
that afatinib could be considered the preferred first-line
treatment option for NSCLC patients with EGFR Del19
mutations, although head-to-head data will be helpful to
confirm this assertion. Furthermore, the improvements in
PFS and PROs observed with afatinib regardless of
mutation type indicate that important clinical benefits are
achieved with afatinib in all patients with common EGFR
mutation-positive NSCLC. Afatinib has also demon-
strated promising activity in patients who have failed on
erlotinib and gefitinib and in patients with active brain
metastases. In patients with SCC of the lung who have
failed on first-line chemotherapy, afatinib significantly
improved PFS, OS, and DCR versus erlotinib. Several
clinical studies are currently ongoing that will help fur-
ther define the role of afatinib in a relapsed/refractory
setting.
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